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A B ST R AC T  
 
Aim: Tadalafil is a potent, selective and reversible inhibitor of phosphodiesterase type 5 (PDE5) 
enzyme breakdowning cyclic guanosine monophosphate (cGMP). In this study, we aimed to 
investigate the effects of tadalafil on nociception, morphine analgesia and tolerance. 
Methods: In this study, 54 Wistar Albino (230-250 g) male rats were used. First of all, four different 
doses (2, 4, 8, 16 mg/kg) were used to determine the optimum effective dose of tadalafil on 
nociception. Optimum activity was found at 8 mg/kg and animals were divided into six groups: Saline 
(S), 8mg/kg tadalafil, 5mg/kg morphine (M), M+ tadalafil, morphine tolerance (MT) and MT+ 
tadalafil. Saline was given to the control group, tadalafil intraperitoneally and morphine 
subcutaneously administered at the indicated doses. To develop tolerance to morphine, 10mg/kg 
morphine was injected daily in the morning and evening for five days and tolerance was evaluated 
with single dose of morphine on sixth days. The resulting analgesic effect was measured with hot 
plate and tail flick analgesia tests and recorded at 30th, 60th, 90th and 120th minutes. 
Results: Tadalafil showed anti-nociceptive effect when given alone at different doses (p<0.05). 
However, tadalafil significantly decreased the analgesic effect of morphine (p<0.05). In addition, 
tadalafil significantly increased the tolerance to morphine (p<0.05). 
Conclusions: The phosphodiesterase type 5 inhibitor tadalafil have anti-nociceptive properties and it 
decreases analgesic effect of morphine, in addition improves tolerance development. These effects 
probably may occur via NO/cGMP pathway. 
Keywords: Phosphodiesterase type 5 inhibitors; tadalafil; nociception; morphine analgesia; 
morphine tolerance.             
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Introduction 
Morphine is an opiate receptor agonist and 
analgesic that is routinely administered in 
cases of strong and chronic pain in clinics. The 
duration of morphine’s effect is reduced by the 
development of tolerance to its anti-
nociceptive properties. Despite the many 
studies that have been made examining the 
development of opioid tolerance, underlying 
mechanisms of tolerance is still unclear. 
Recent studies propose that an endogenous 
molecule nitric oxide (NO), linked to the 
regulation of many physiological and 
pathological pathways, is involved in the 
morphine tolerance development [1, 2, 3]. 
Moreover, it has been seen that these effects of 
NO may be associated with cyclic guanosine 
monophosphate (cGMP) [4]. 
Tadalafil, a selective phosphodiesterase-5 
(PDE5) inhibitor, enables the removal of 
cGMP, one of the main factors bringing about 
smooth muscle relaxation. Given their 
effectiveness in improving nitric oxide-driven 
cGMP collection and maintaining the causes of 
vasodilatation in corpus cavernosum, PDE5 
inhibitors are generally prescribed for the 
treatment of erectile dysfunction (ED) in male 
[5]. Many studies have been made recently into 
PDE-5 suggesting their possible applications 
in areas other than ED [6, 7]. It has been shown 
to have anti-oxidant properties in that it 
decreases 3,4-Methylenedioxyamphetamine 
and increases superoxide dismutase and 
catalyzes enzyme activity in rat ovary tissue 
following ischemia/reperfusion injury [8]. In 
addition, it has an anti-oxidant effect in 
ischemia/reperfusion injury in rat brain tissue 
[9]. Furthermore, it has been demonstrated that 
the anti-inflammatory cytokine IL-10 was 
increased in the tadalafil-treated diabetic 
model in mice [10]. It has also been 
demonstrated that tadalafil is useful in the 
treatment of structural detrusor changes, 
hypoxia, and bladder compliance after 
cavernous nerve injury [11]. 
Sildenafil and vardenafil are other known 
PDE5 inhibitors. Several studies into sildenafil 
and vardenafil using various experimental 
nociceptive models have shown that they have 
anti-nociceptive properties [12, 13]. The aim 
of current study was to examine the possible 
involvement of tadalafil in nociception, 
morphine analgesia and morphine tolerance 
development in rats. 
 
Methods 
 
Animals 
Wistar Albino rats (230-250 g, n=6 for each 
group) were acquired from the Laboratory 
Animal Center of Cumhuriyet University 
(Sivas, Turkey). The rats were maintained 
under standard situations: 12-h light–dark 
cycle (lights turn on at 08:00 A.M.) with ad 
libitum food and water and a constant 
temperature (22±2 °C). All the experiments 
were performed between 09:00 and 17:00. The 
animals were handled and the procedures were 
carried out in accordance with the guidelines 
provided by the National Institute of Health 
detailed in the “Principles of animal laboratory 
care”. The experimental protocols were 
approved by the Cumhuriyet University 
Animal Ethics Committee. 
 
Drugs 
The morphine sulfate and tadalafil (Cialis® 20 
mg tablets, Lilly) were dissolved in saline 
solution. The drugs were freshly dissolved on 
the days of experimentation. Morphine (5 
mg/kg) was administered subcutaneously (s.c.) 
[4] and tadalafil (2, 4, 8, 16 mg/kg) 
intraperitoneally (i.p.) before the analgesia 
tests. 
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Induction of morphine tolerance 
In order to induce morphine tolerance, the rats 
were selected at random and treated s.c. with 
10 mg/kg morphine twice a day (09:00 and 
17:00) for five days.  Furthermore, morphine 
(10 mg/kg) applied 30 min after each tadalafil 
injection for five days in order to determine the 
effects of tadalafil (8 mg/kg, i.p.) on morphine 
tolerance. The optimal analgesic dose of 
morphine (5 mg/kg, s.c.) was given on the sixth 
day without saline or tadalafil and the tail-flick 
and hot-plate tests were measured at 30-min 
intervals (30, 60, 90, and 120 min) in order to 
evaluate the degree of tolerance. 
 
Antinociception tests 
Tail-flick test 
We made use of a standard tail flick device 
(May TF 0703 Tail-flick Unit, Commat, 
Turkey) to measure thermal nociception. The 
radiant heat source was focused on the distal 
portion of the tail at a distance of 3 cm in each 
measurement after the administration of saline 
or the study’s drugs. Tail-flick latencies (TFL) 
were obtained once the saline or drugs had 
been administered. The cut-off latency time 
was adjusted to 15 s to prevent tissue injury. 
The hyperalgesic response in the tail-
withdrawal test is generally attributed to the 
central mechanisms of pain [14, 15].  
 
Hot-plate test 
The anti-nociceptive reaction on the hot-plate 
is thought to stem from a combination of 
central and peripheral mechanisms [14]. In this 
test, the animals were placed individually on a 
hot-plate (May AHP 0603 Analgesic Hot-plate 
Commat, Turkey) with the temperature 
calibrated to 54±3°C. The latency to the first 
sign of paw licking or jump reaction to avoid 
the heat was taken as an indicator of the pain 
threshold. The cut-off time was 30 s to prevent 
damage to the paw. 
 
Experimental protocols 
The analgesic effects of tadalafil and morphine 
were evaluated at 30-min intervals (30, 60, 90, 
and 120 min) using tail-flick and hot-plate 
tests. Doses administered i.p. at 2, 4, 8, 16 
mg/kg were administered in order to evaluate 
the effective dose of tadalafil on nociception. 
Optimum activity was found at a dose of 
8mg/kg. The animals were divided into six 
groups: Saline (S), 8mg/kg tadalafil, 5mg/kg 
morphine (M), M+ tadalafil, morphine 
tolerance (MT) and MT+ tadalafil. Saline and 
tadalafil were administered i.p. and morphine 
was administered s.c. at the indicated doses 
(volume of administration, 1 ml/kg). 
 
Data analysis 
To calculate the percentages of maximum anti-
nociceptive effect (% MPE) the tail-flick and 
hot-plate latencies (which are in seconds) were 
converted to the percentage of anti-nociceptive 
effectiveness using this equation: % MPE = 
[(Post drug latency – Baseline latency) / 
(Cutoff value – Baseline latency)] ×100. 
 
Statistical analysis 
All experimental results were expressed as 
mean ± SEM (standard error of the mean). The 
anti-nociceptive effect was measured and the 
mean % MPEs were calculated for all groups. 
The data were analyzed using analysis of 
variance (one-way anova) followed by a post-
hoc Tukey test. A significant difference was 
defined as a p value <0.05. 
 
Results 
The effect of different doses of tadalafil on 
nociception 
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To examine optimal dose of tadalafil, the 
analgesic response were evaluated for 2, 4, 8 
and 16 mg/kg doses of tadalafil at 30 min 
intervals during two hours by the analgesia 
tests. All the dose groups showed anti-
nociceptive effects compared to the saline 
group at 30, 60, 90, and 120 minutes in both 
tail flick test (p<0.05; Figure 1A) and hot plate 
test (p<0,05; Figure 1B). However, the 
maximum analgesic effect was found at 60 min 
after the administration of 8 mg/kg tadalafil 
(27.5±0.7 for tail-flick and 13.0±0.6 for hot-
plate test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antinociceptive effect of 8 mg/kg dose of 
tadalafil was significantly higher than 2 mg/kg, 
4 mg/kg, 16 mg/kg tadalafil and saline groups 
in both tail-flick test (p<0.05; Figure 1A) and 
hot-plate test (p<0.05; Figure 1B). 
 
The effect of tadalafil on morphine analgesia 
The findings demonstrated that tadalafil 
significantly reduces the antinociceptive effect 
of morphine in both tail-flick test (p<0.05; 
Figure 2A) and hot plate test (p<0.05; Figure 
2B) compared to the morphine group. 
Furthermore the maximum decreasing effect of  
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tadalafil on morphine was detected at 60 min 
in the tail-flick test (56.8±4.0) and hot-plate 
test (28.1±3.1). 
The effect of tadalafil on morphine tolerance 
development 
The morphine group’s % MPE value was 
statistically higher than the morphine-tolerant  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
group in both the tail-flick test (p<0.05; Figure 
3A) and hot plate test (p<0.05; Figure 3B). 
Tadalafil in combination with morphine 
produced a significantly increased morphine 
tolerance development in both the tail-flick test 
(p<0.05; Figure 3A) and hot plate test (p<0.05; 
Figure 3B). 
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Discussion 
In this study, we suggest that tadalafil is able 
to produce peripheral anti-nociception in both 
tail flick and hot plate analgesia tests. Tadalafil 
is a strong, selective and reversible 
phosphodiesterase 5 inhibitor that inhibits 
cyclic GMP breakdown [16].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In previous studies with PDE 5 inhibitors, it 
was shown that they have peripheral anti-
nociceptive effects by increasing intracellular 
cGMP levels [12,13]. In contrast to our study, 
one study showed that the PDE 5 inhibitor 
sildenafil had anti-nociceptive effects on acetic  
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acid and carrageenan-induced hyperalgesia but 
not in tail flick test and hot plate test [17]. In 
addition to our study, another study showed 
that the PDE 5 inhibitor sildenafil enhanced 
diclofenac anti-nociceptive effects in formalin 
tests [18]. Furthermore, one study 
demonstrated that the PDE 5 inhibitor tadalafil 
has analgesic effects on experimental arthritis 
by suppressing TNF alpha release in joints 
[19]. In contrast to these studies, it has been 
suggested that zaprinast, another PDE 5 
inhibitor, has no effect on hyperalgesia 
induced by prostaglandin E2 [20]. The 
differences may be a result of the various 
models of pain utilized, since agents with 
direct inflammatory stimulus like 
prostaglandin E might not activate the 
arginine-NO-cyclic GMP track. However, this 
pathway seems to be stimulated by agents 
administered with an inflammatory stimulus 
such as carrageenan, formalin or uric acid [21, 
22], and may not even be an inflammatory 
pathway like in our study.  
Opioid drugs like morphine activate opioid 
receptors, which are a family of G protein-
coupled receptors that mainly signal through 
heterotrimeric G protein G I/O subunits. When 
an agonist binds to opioid receptors, the 
activation of receptors causes a signal that 
inhibits adenylate cyclase and calcium 
channels. There are four types of opioid 
receptors: µ, δ, κ and nociceptin/orphanin FQ. 
Activation of all four types of receptors could 
produce analgesia, whereas tolerance is mainly 
related to the activation of µ-opioid receptors 
[23]. In contrast to a previous study by ixcoatl-
Zecuatl et al [17], our study showed that the 
PDE 5 inhibitor tadalafil decreased the 
analgesic effects of morphine while increasing 
the development of morphine tolerance [17]. 
Tolerance is characterized as a decrease in 
effect following prolonged drug administration 
giving rise to a loss of drug efficiency, which 
was sufficient to cause analgesia in the 
beginning [24]. The mechanisms behind the 
development of tolerance to the analgesic 
effects of opioids are unclear and more studies 
are needed. Opioid tolerance development 
could involve changes in opioid and non-
opioid mechanisms. Researchers have reported 
various different pathways in the 
developmental process of morphine tolerance 
[25, 26, 27]. To begin with, one of these 
mechanisms is the NO signaling pathway [2]. 
NO has been implicated in the central and 
peripheral nervous system as a biological 
messenger molecule [28, 29, 30]. It is derived 
from the L-arginine amino acid by means of 
the nitric oxide synthase enzyme (NOS). NOS 
activation and NO release stimulate the soluble 
guanylyl cyclase (sGC), which causes a rise in 
the levels of cyclic GMP in the cells [31, 32]. 
In a previous study, it was demonstrated that 
NO-independent sGC activators (YC-1 and 
BAY 41-2272) and NO donor (SNAP) 
combined with the morphine increased the rate 
of morphine tolerance like our study [4]. But, 
another study has suggested that sGC 
inhibitors (LY-83,583 and methylene blue) 
reduced morphine tolerance development [33]. 
These results suggest that the cyclic GMP 
pathway might play a role in the development 
of morphine tolerance. 
Furthermore, there are the other mechanisms 
that can contribute to opioid tolerance such as 
desensitization and internalization, which are 
major pathways for tolerance. This pathway is 
formed by the activation of cyclic adenosine 
monophosphate (cAMP) protein kinase A 
(PKA) [34]. In addition, glutamate has a 
crucial effect on the increase of cAMP in this 
pathway and the development of tolerance 
[35]. Furthermore, NO/cGMP signaling leads 
to an increase in glutamate release [36]. 
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Therefore, this indirect mechanism may be the 
reason for the possible effects of tadalafil on 
tolerance. 
In conclusion, we found that the PDE 5 
inhibitor tadalafil has anti-nociceptive effects 
at different doses. Moreover, tadalafil 
decreases the analgesic effect of morphine and 
increases the tolerance to morphine. In the 
light of this evidence, we propose that the 
intracellular nitric oxide–cGMP signaling 
pathway may play a role in both peripheral 
anti-nociception and the development of 
morphine tolerance. 
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